Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

AAV gene therapy for Tay-Sachs disease

Nature Medicine volume 28, pages 251–259 (2022)Cite this article

Subjects

Abstract

Tay-Sachs disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Here, we describe an adeno-associated virus (AAV) gene therapy expanded-access trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no secondary endpoints. Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 1014 vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction. Patient TSD-002 was treated at 7 months by combined bilateral thalamic (1.5 × 1012 vg per thalamus) and i.t. infusion (3.9 × 1013 vg). Both patients were immunosuppressed. Injection procedures were well tolerated, with no vector-related adverse events (AEs) to date. Cerebrospinal fluid (CSF) HexA activity increased from baseline and remained stable in both patients. TSD-002 showed disease stabilization by 3 months after injection with ongoing myelination, a temporary deviation from the natural history of infantile TSD, but disease progression was evident at 6 months after treatment. TSD-001 remains seizure-free at 5 years of age on the same anticonvulsant therapy as before therapy. TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Longitudinal safety and immunological studies.
Fig. 2: Longitudinal biochemical and neurological function outcome measures.
Fig. 3: Anatomical MRI findings in patients with TSD who were treated with rAAVrh8.HEX/HEXB vectors.
Fig. 4: DTI in TSD patients treated with rAAVrh8.HEX/HEXB vectors.

Data availability

Requests for data presented in this article should be addressed to the corresponding authors (miguel.esteves@umassmed.edu or terry.flotte@umassmed.edu) and will be reviewed individually. Requests will be answered within 30 days from the date they are received. The data available for sharing include the study protocol, raw data for ELISpot assays, GM2 ganglioside quantification in CSF, hexosaminidase activity levels in serum and CSF and MRI data. All shared data will be deidentified to protect patient privacy. A data transfer and use agreement may be required after evaluation by the UMass Chan Medical School Office of Technology Management. The MRI Atlas of Myelination (www.myelinationmriatlas.com) was the data source in 7- and 12-month-old healthy children shown in Extended Data Fig. 1. Source data are provided with this paper.

References

  1. Bley, A. E. et al. Natural history of infantile G(M2) gangliosidosis. Pediatrics 128, e1233–e1241 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).

    Article  CAS  PubMed  Google Scholar 

  3. Muramatsu, S. et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease. Mol. Ther. 18, 1731–1735 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hwu, W. L. et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med. 4, 134ra161 (2012).

    Article  Google Scholar 

  5. Passini, M. A. et al. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol. 77, 7034–7040 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450–459 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Samaranch, L. et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24, 526–532 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hinderer, C. et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol. Ther. 22, 2018–2027 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Meyer, K. et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol. Ther. 23, 477–487 (2015).

    Article  CAS  PubMed  Google Scholar 

  10. Miyanohara, A. et al. Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Mol. Ther. Methods Clin. Dev. 3, 16046 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cearley, C. N. et al. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16, 1710–1718 (2008).

    Article  CAS  PubMed  Google Scholar 

  12. Salegio, E. A. et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther. 20, 348–352 (2013).

    Article  CAS  PubMed  Google Scholar 

  13. Passini, M. A., Lee, E. B., Heuer, G. G. & Wolfe, J. H. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci. 22, 6437–6446 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kells, A. P. et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl Acad. Sci. USA 106, 2407–2411 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Baek, R. C. et al. AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS One 5, e13468 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cearley, C. N. & Wolfe, J. H. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27, 9928–9940 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dodge, J. C. et al. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc. Natl Acad. Sci. USA 102, 17822–17827 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Foust, K. D., Flotte, T. R., Reier, P. J. & Mandel, R. J. Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat. Hum. Gene Ther. 19, 71–82 (2008).

    Article  CAS  PubMed  Google Scholar 

  19. Cachon-Gonzalez, M. B. et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc. Natl Acad. Sci. USA 103, 10373–10378 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cachon-Gonzalez, M. B. et al. Gene transfer corrects acute GM2 gangliosidosis–potential therapeutic contribution of perivascular enzyme flow. Mol. Ther. 20, 1489–1500 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gray-Edwards, H. et al. AAV gene therapy in a sheep model of Tay-Sachs disease. Hum. Gene Ther. 29, 312–326 (2018).

    Article  CAS  PubMed  Google Scholar 

  22. Rockwell, H. E. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system. ASN Neuro. 7, 1759091415569908 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  23. Taghian, T. et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna.Mol. Ther. 28, 411–421 (2020).

    Article  CAS  PubMed  Google Scholar 

  24. Schneck, L., Maisel, J. & Volk, B. W. The startle response and serum enzyme profile in early detection of Tay-Sachs’ disease. J. Pediatr. 65, 749–756 (1964).

    Article  CAS  PubMed  Google Scholar 

  25. Mueller, C. et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N. Engl. J. Med. 383, 151–158 (2020).

    Article  CAS  PubMed  Google Scholar 

  26. Singh, A. MRI Atlas of Normal Myelination www.myelinationmriatlas.com (2017).

  27. Hermoye, L. et al. Pediatric diffusion tensor imaging: normal database and observation of the white matter maturation in early childhood. Neuroimage 29, 493–504 (2006).

    Article  PubMed  Google Scholar 

  28. Mahuran, D. J. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim. Biophys. Acta 1455, 105–138 (1999).

    Article  CAS  PubMed  Google Scholar 

  29. Neudorfer, O. et al. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet. Med. 7, 119–123 (2005).

    Article  CAS  PubMed  Google Scholar 

  30. Wendeler, M. & Sandhoff, K. Hexosaminidase assays. Glycoconj. J. 26, 945–952 (2009).

    Article  CAS  PubMed  Google Scholar 

  31. Baek, R. C., Martin, D. R., Cox, N. R. & Seyfried, T. N. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44, 197–205 (2009).

    Article  CAS  PubMed  Google Scholar 

  32. Hepbildikler, S. T., Sandhoff, R., Kolzer, M., Proia, R. L. & Sandhoff, K. Physiological substrates for human lysosomal beta-hexosaminidase S. J. Biol. Chem. 277, 2562–2572 (2002).

    Article  CAS  PubMed  Google Scholar 

  33. Golebiowski, D. et al. Direct intracranial injection of AAVrh8 encoding monkey beta-N-acetylhexosaminidase causes neurotoxicity in the primate brain. Hum. Gene Ther. 28, 510–522 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bradbury, A. M. et al. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy. Mol. Ther. 21, 1306–1315 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. McCurdy, V. J. et al. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. Gene Ther. 22, 181–189 (2015).

    Article  CAS  PubMed  Google Scholar 

  36. Gray-Edwards, H. L. et al. Adeno-associated virus gene therapy in a sheep model of Tay-Sachs disease. Hum. Gene Ther. 29, 312–326 (2018).

    Article  CAS  PubMed  Google Scholar 

  37. Taghian, T. et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol. Ther. 28, 411–421 (2020).

    Article  CAS  PubMed  Google Scholar 

  38. Snyder, P. D. Jr., Krivit, W. & Sweeley, C. C. Generalized accumulation of neutral glycosphingolipids with G M2 ganglioside accumulation in the brain. J. Lipid Res. 13, 128–136 (1972).

    Article  CAS  PubMed  Google Scholar 

  39. Abe, T., Ogawa, K., Fuziwara, H., Urayama, K. & Nagashima, K. Spinal ganglia and peripheral nerves from a patent with Tay-Sachs disease. Morphological and ganglioside studies. Acta Neuropathol. 66, 239–244 (1985).

    Article  CAS  PubMed  Google Scholar 

  40. Rapin, I., Suzuki, K. & Valsamis, M. P. Adult (chronic) GM2 gangliosidosis: atypical spinocerebellar degeneration in a Jewish sibship. Arch. Neurol. 33, 120–130 (1976).

    Article  CAS  PubMed  Google Scholar 

  41. Tutunji, R. et al. Thalamic volume and dimensions on MRI in the pediatric population: normative values and correlations: a cross-sectional study. Eur. J. Radiol. 109, 27–32 (2018).

    Article  PubMed  Google Scholar 

  42. Taghian, T. et al. Volume and infusion rate dynamics of intraparenchymal central nervous system infusion in a large animal model. Hum. Gene Ther. 31, 617–625 (2020).

    Article  CAS  PubMed  Google Scholar 

  43. Corti, M. et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol. Ther. Methods Clin. Dev. 1, 14033 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  44. Miyazaki, J. et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 79, 269–277 (1989).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the BlueGenes Foundation, which had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We are also grateful for the exceptional support from the National Tay-Sachs and Allied Diseases Association and the Cure Tay-Sachs Foundation during the preclinical development of this AAV gene therapy. We thank the families that provided MRI images from their deceased children with TSD or SD to support this study. We thank A. Singh for allowing us to use the MRI images from healthy children at 7 and 12 months of age for comparison purposes. We thank A. Zimmerman and B. Wong for their assistance during this study. We also thank N. Sanil and C. Dooley in the research pharmacy for their assistance in preparing the AAV doses for administration. We acknowledge the NEALS Biorepository for providing the biofluids from patient with amyotrophic lateral sclerosis used as non-TSD control samples in this study. M. Sena-Esteves was the sponsor of the clinical trial and was responsible for production of the AAVrh8 vectors in his laboratory as described in Methods. The hexosaminidase assays and western blots were also done in his laboratory. He had no role in the clinical aspects of the trial. During the manuscript review process, R.F. passed away in August 2021.

Author information

Authors and Affiliations

  1. Department of Pediatrics, UMass Chan Medical School, Worcester, MA, USA

    Terence R. Flotte, Oguz Cataltepe, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Scot Bateman, Allison M. Keeler & Laura Gibson

  2. Horae Gene Therapy Center and The Li Weibo Institute for Rare Diseases Research, UMass Chan Medical School, Worcester, MA, USA

    Terence R. Flotte, Ana Rita Batista, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Allison M. Keeler, Robert H. Brown Jr., Heather L. Gray-Edwards & Miguel Sena-Esteves

  3. Department of Neurosurgery, UMass Chan Medical School, Worcester, MA, USA

    Oguz Cataltepe & Richard Moser

  4. Department of Radiology, UMass Chan Medical School, Worcester, MA, USA

    Ajit Puri, Aly Abayazeed, Saurabh Rohatgi, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis & Heather L. Gray-Edwards

  5. Department of Neurology, UMass Chan Medical School, Worcester, MA, USA

    Ana Rita Batista, Diane McKenna-Yasek, Catherine Douthwright, Robert H. Brown Jr. & Miguel Sena-Esteves

  6. Department of Medicine and Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA

    Xuntian Jiang

  7. Departments of Anesthesiology and Perioperative Medicine, UMass Chan Medical School, Worcester, MA, USA

    Spiro G. Spanakis & Julia Parzych

  8. Department of Internal Medicine, UMass Chan Medical School, Worcester, MA, USA

    Laura Gibson & Robert Finberg

  9. Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA

    Bruce A. Barton

  10. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

    Cynthia J. Tifft

  11. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Florian S. Eichler

  12. Scott-Ritchey Research Center, Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA

    Douglas R. Martin

Authors
  1. Terence R. Flotte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oguz Cataltepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ajit Puri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Rita Batista
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard Moser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diane McKenna-Yasek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Catherine Douthwright
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gwladys Gernoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Meghan Blackwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Christian Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Phillip W. L. Tai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xuntian Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Scot Bateman
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Spiro G. Spanakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Julia Parzych
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Allison M. Keeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Aly Abayazeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Saurabh Rohatgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Laura Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Robert Finberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Bruce A. Barton
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Zeynep Vardar
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Mohammed Salman Shazeeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Matthew Gounis
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Cynthia J. Tifft
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Florian S. Eichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Robert H. Brown Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Douglas R. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Heather L. Gray-Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Miguel Sena-Esteves
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

T.R.F., R.H.B., O.C., R.M., A.P., S.B., S.G.S., J.P., A.A., L.G., C.J.T., R.F. and F.S.E. were part of the medical team. D.M.-Y., C.D. and A.M.K. were part of the clinical trial coordination team, data collection and analysis. P.W.L.T. analyzed the NGS data for the plasmids used in vector production. A.R.B. and M.S.-E. produced the AAVrh8 vectors. G.W., M.B. and C.M. performed all immunological assays and respective data interpretation. A.R.B. performed all enzyme assays and western blots, as well as respective data analysis and interpretation. B.A.B. performed the statistical analyses. A.A., S.R., Z.V., M.S.S. and M.G. were responsible for analysis and interpretation of MRI data. T.R.F., R.H.B., D.R.M., H.L.G.-E. and M.S.-E. wrote the manuscript.

Corresponding authors

Correspondence to Terence R. Flotte or Miguel Sena-Esteves.

Ethics declarations

Competing interests

The University of Massachusetts Chan Medical School licensed the AAV vectors to Axovant Gene Therapies (now Sio Gene Therapies) in December 2018. Licensing revenue is shared with Auburn University and M.S.-E., D.R.M. and H.G.-E. receive part of the licensing revenue according to institutional policies. The schedule of licensing payments is governed by accomplishment of milestones related to an ongoing phase 1/2 clinical trial where the investigators named above have no role. The remaining authors declare no competing interests.

Peer review

Peer review information

Nature Medicine thanks Timothy Yu, Steven Gray and Guilherme Baldo for their contribution to the peer review of this work. Anna Maria Ranzoni was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Structural brain MRI in healthy children during development and an infantile TSD patient.

T2 brain MRIs at 7 and 12 months of age in healthy children are from the MRI Atlas of Normal Myelination (www.myelinationmriatlas.com) with permission from Dr. Achint Singh. The T2 brain MRI of an 11-month-old infantile Tay-Sachs disease child was kindly provided by a family of a deceased child through the National Tay-Sachs and Allied Disease Association with permission to publish it here.

Extended Data Fig. 2 Volumetric calculations of lateral ventricular size and size of the lentiform nucleus.

TSD-001 has larger ventricles consistent with cortical atrophy whereas the relevance of TSD-002 ventricular size remains unclear and could be associated with normal brain development.

Extended Data Fig. 3 DTI of normal brain development.

Tractography of the normal developing brain from Hermoye et al, 2006. The color scheme of the tractography pathways is based on a standard red-green-blue (RGB) color code that shows the spatial locations of terminal regions of each pathway (right-left: red; dorsal-ventral: blue; and, anterior-posterior: green.

Extended Data Fig. 4 DTI results.

a, Mean diffusivity (MD) maps of TSD-002 brain indicating regions of interest (ROI) for calculation of DTI parameters. MD quantifications over time are displayed below the images for various ROIs in the brain for both TSD-001 and TSD-002. b, Axial diffusivity (AD) and c, radial diffusivity (RD) measurements are also shown for the same brain ROIs over time for both patients. Data is represented as mean ± SD of pixel intensity in the ROI. In TSD-002 both optic radiations show stable FA values and increased average diffusivity values. AD values remain stable even when FA decreases, as shown in the anterior corpus callosum for TSD-001.

Supplementary information

Supplementary Information

Supplementary Methods, Tables 1 and 2, Redacted certificates of analysis of AAV vector lots used in clinical trial

Reporting Summary

Source data

Source Data Fig. 1

Unprocessed western blots.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Flotte, T.R., Cataltepe, O., Puri, A. et al. AAV gene therapy for Tay-Sachs disease. Nat Med 28, 251–259 (2022). https://doi.org/10.1038/s41591-021-01664-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01664-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing